Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs.
Fiche publication
Date publication
août 2015
Journal
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BERNARD Alain, Pr GHIRINGHELLI François, Dr PAGES Pierre-Benoit, Dr CHARON-BARRA Céline, Dr DERANGERE Valentin
Tous les auteurs :
Pagès PB, Derangere V, Bouchot O, Magnin G, Charon-Barra C, Lokiec F, Ghiringhelli F, Bernard A
Lien Pubmed
Résumé
Colorectal cancer is the third most commonly diagnosed cancer worldwide, with up to 25% of patients presenting with metastases at the time of diagnosis. Despite pulmonary metastasectomy many patients go on to develop pulmonary recurrence, which might be linked to the presence of lung micrometastases. In this setting, the adjuvant administration of high-dose chemotherapy by isolated lung perfusion (ILP) has shown encouraging results. However, the tolerance to and efficacy of modern gemcitabine (GEM)-based chemotherapy regimens during adjuvant ILP remain unknown. We conducted a dose-escalating preclinical study to evaluate the immediate and delayed toxicity of GEM in a pig model to define dose-limiting toxicity (DLT) and maximum tolerated concentration.
Mots clés
Acute Disease, Acute Lung Injury, chemically induced, Anesthesia, General, methods, Animals, Antimetabolites, Antineoplastic, administration & dosage, Chemotherapy, Cancer, Regional Perfusion, adverse effects, Deoxycytidine, administration & dosage, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, methods, Female, Lung, metabolism, Lung Neoplasms, drug therapy, Sus scrofa
Référence
Eur J Cardiothorac Surg. 2015 Aug;48(2):228-35